Literature DB >> 19162429

Low rates of loco-regional recurrence following extended lymph node dissection for gastric cancer.

A Muratore1, G Zimmitti, R Lo Tesoriere, A Mellano, P Massucco, L Capussotti.   

Abstract

AIM: The study by MacDonald et al. [Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30] has reported low loco-regional recurrence rates (19%) after gastric cancer resection and adjuvant radiotherapy. However, the lymph node dissection was often "inadequate". The aim of this retrospective study is to analyse if an extended lymph node dissection (D2) without adjuvant radiotherapy may achieve comparable loco-regional recurrence rates.
METHODS: A prospective database of 200 patients who underwent a curative resection for gastric carcinoma from January 2000 to December 2006 was analysed. D2 lymph node dissection was standard. Recurrences were categorized as loco-regional, peritoneal, or distant. No patients received neoadjuvant or adjuvant radiotherapy.
RESULTS: The in-hospital mortality rate was 1% (2 patients). The mean number of dissected lymph nodes was 25.9. Overall and disease-free survival at 5years were 60.7% and 61.2% respectively. During the follow-up, 60 patients (30%) have recurred at 76 sites: 38 (50%) distant metastases, 25 (32.9%) peritoneal metastases, and 13 (17.1%) loco-regional recurrences. The loco-regional recurrence was isolated in 6 patients and associated with peritoneal or distant metastases in 7 patients. The mean time to the first recurrence was 18.9 (95% confidence interval: 15.0-21.9) months.
CONCLUSIONS: Extended lymph node dissection is safe and warrants low loco-regional recurrence rates.

Entities:  

Mesh:

Year:  2009        PMID: 19162429     DOI: 10.1016/j.ejso.2008.12.012

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

1.  Comparative study of laparoscopic vs open gastrectomy in gastric cancer management.

Authors:  Giuseppe S Sica; Edoardo Iaculli; Livia Biancone; Sara Di Carlo; Rosa Scaramuzzo; Cristina Fiorani; Paolo Gentileschi; Achille L Gaspari
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

Review 2.  Gastrointestinal cancer metastasis and lymphatic advancement.

Authors:  Kazuhide Kumagai; Kouji Shimizu; Noboru Yokoyama; Sadatsugu Aida; Takayuki Tanaka; Kennichi Yamagata
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

3.  Self-expandable metallic stent placement for malignant obstruction in patients with locally recurrent gastric cancer.

Authors:  Jaihwan Kim; Il Ju Choi; Chan Gyoo Kim; Jong Yeul Lee; Soo-Jeong Cho; Sook Ryun Park; Jun Ho Lee; Keun Won Ryu; Young-Woo Kim; Young-Iee Park
Journal:  Surg Endosc       Date:  2010-10-26       Impact factor: 4.584

4.  Establishment and identification of a rabbit model of peritoneal carcinomatosis from gastric cancer.

Authors:  Lie-Jun Mei; Xiao-Jun Yang; Li Tang; Alaa Hammed Al-Shammaa Hassan; Yutaka Yonemura; Yan Li
Journal:  BMC Cancer       Date:  2010-04-01       Impact factor: 4.430

Review 5.  Do all the European surgeons perform the same D2? The need of D2 audit in Europe.

Authors:  Maria Bencivenga; Giuseppe Verlato; Valentina Mengardo; Jacopo Weindelmayer; William H Allum
Journal:  Updates Surg       Date:  2018-06-04

6.  A remark on: do all the European surgeons perform the same D2? The need for D2 audit in Europe.

Authors:  Dezső Tóth
Journal:  Updates Surg       Date:  2018-11-20

7.  Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis.

Authors:  Deepa Magge; Mazen Zenati; Arun Mavanur; Joshua Winer; Lekshmi Ramalingam; Heather Jones; Amer Zureikat; Matthew Holtzman; Kenneth Lee; Steven Ahrendt; James Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-11-07       Impact factor: 5.344

8.  Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer.

Authors:  Jing-lei Qu; Xin Li; Xiu-Juan Qu; Zhi-tu Zhu; Li-zhong Zhou; Yue-e Teng; Jing-dong Zhang; Bo Jin; Ming-fang Zhao; Ping Yu; Yun-peng Liu
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

9.  Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center.

Authors:  Wilson L Costa; Felipe J F Coimbra; Ricardo C Fogaroli; Héber S C Ribeiro; Alessandro L Diniz; Maria Dirlei F L Begnami; Celso A L Mello; Marcelo F Fanelli; Milton J B Silva; José Humberto Fregnani; André L Montagnini
Journal:  Radiat Oncol       Date:  2012-10-15       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.